BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 16873074)

  • 1. [Place of anatomopathology in evaluation of response to neoadjuvant chemotherapy. Prognostic and predictive markers: example of breast cancer].
    Abrial C; Bouchet-Mishellany F; Raoelfils I; Cayre A; Curé H; Chollet P; Penault-Llorca F
    Bull Cancer; 2006 Jul; 93(7):663-8. PubMed ID: 16873074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Roles of the pathologist in neoadjuvant chemotherapy: evaluation of response, prognostic and predictive factors].
    Penault-Llorca F; Vincent-Salomon A
    Ann Pathol; 2003 Dec; 23(6):555-63. PubMed ID: 15094593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures.
    Rody A; Karn T; Gätje R; Kourtis K; Minckwitz G; Loibl S; Munnes M; Ruckhäberle E; Holtrich U; Kaufmann M; Ahr A
    Zentralbl Gynakol; 2006 Apr; 128(2):76-81. PubMed ID: 16673249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Breast cancer and neoadjuvant therapy: any predictive marker?
    Vyzula R; Dusek L; Zaloudík J; Demlová R; Klimes D; Selvekerová S
    Neoplasma; 2004; 51(6):471-80. PubMed ID: 15640958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Neoadjuvant treatment of breast cancer: implications for the pathologist].
    Le Guellec S; Perallon R; Alunni JP; Charitansky H; Leaha C; Gonzalez AM; Chateau MC; Simony-Lafontaine J; Jacot W; Gutowski M; Penault-Llorca F; Dalenc F; Lacroix-Triki M
    Ann Pathol; 2011 Dec; 31(6):442-54. PubMed ID: 22172117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of HER-2/neu amplification and other biological markers as predictors of response to neoadjuvant anthracycline-based chemotherapy in primary breast cancer: the role of anthracycline dose intensity.
    Bozzetti C; Musolino A; Camisa R; Bisagni G; Flora M; Bassano C; Martella E; Lagrasta C; Nizzoli R; Personeni N; Leonardi F; Cocconi G; Ardizzoni A
    Am J Clin Oncol; 2006 Apr; 29(2):171-7. PubMed ID: 16601438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Scarff-Bloom-Richardson (SBR) grading: a pleiotropic marker of chemosensitivity in invasive ductal breast carcinomas treated by neoadjuvant chemotherapy.
    Amat S; Penault-Llorca F; Cure H; Le Bouedëc G; Achard JL; Van Praagh I; Feillel V; Mouret-Reynier MA; Dauplat J; Chollet P
    Int J Oncol; 2002 Apr; 20(4):791-6. PubMed ID: 11894126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biological markers as predictive factors of response to neoadjuvant taxanes and anthracycline chemotherapy in breast carcinoma.
    Zhou B; Yang DQ; Xie F
    Chin Med J (Engl); 2008 Mar; 121(5):387-91. PubMed ID: 18364105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of Ki-67 proliferation and apoptotic index before, during and after neoadjuvant chemotherapy for primary breast cancer.
    Burcombe R; Wilson GD; Dowsett M; Khan I; Richman PI; Daley F; Detre S; Makris A
    Breast Cancer Res; 2006; 8(3):R31. PubMed ID: 16790076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lessons on responsiveness to adjuvant systemic therapies learned from the neoadjuvant setting.
    Colleoni M; Viale G; Goldhirsch A
    Breast; 2009 Oct; 18 Suppl 3():S137-40. PubMed ID: 19914533
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High prognostic significance of residual disease after neoadjuvant chemotherapy: a retrospective study in 710 patients with operable breast cancer.
    Abrial SC; Penault-Llorca F; Delva R; Bougnoux P; Leduc B; Mouret-Reynier MA; Mery-Mignard D; Bleuse JP; Dauplat J; Curé H; Chollet P
    Breast Cancer Res Treat; 2005 Dec; 94(3):255-63. PubMed ID: 16267618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
    Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
    J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
    [TBL] [Abstract][Full Text] [Related]  

  • 13. alphaB-crystallin is a novel predictor of resistance to neoadjuvant chemotherapy in breast cancer.
    Ivanov O; Chen F; Wiley EL; Keswani A; Diaz LK; Memmel HC; Rademaker A; Gradishar WJ; Morrow M; Khan SA; Cryns VL
    Breast Cancer Res Treat; 2008 Oct; 111(3):411-7. PubMed ID: 17968656
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Preoperative chemotherapy in breast cancer and the development of new predictive markers].
    Denkert C; Schickling O; von Minckwitz G
    Verh Dtsch Ges Pathol; 2006; 90():114-23. PubMed ID: 17867587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer.
    Gajdos C; Tartter PI; Estabrook A; Gistrak MA; Jaffer S; Bleiweiss IJ
    J Surg Oncol; 2002 May; 80(1):4-11. PubMed ID: 11967899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant chemotherapy for locally advanced breast cancer results in alterations in preoperative tumor marker status.
    Piper GL; Patel NA; Patel JA; Malay MB; Julian TB
    Am Surg; 2004 Dec; 70(12):1103-6. PubMed ID: 15663054
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome.
    Faneyte IF; Schrama JG; Peterse JL; Remijnse PL; Rodenhuis S; van de Vijver MJ
    Br J Cancer; 2003 Feb; 88(3):406-12. PubMed ID: 12569384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of neoadjuvant chemotherapy on histologic grade, hormone receptor status, and HER2/neu status in breast carcinoma.
    Adams AL; Eltoum I; Krontiras H; Wang W; Chhieng DC
    Breast J; 2008; 14(2):141-6. PubMed ID: 18248553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biomarker discordance pre and post neoadjuvant chemotherapy in breast cancer.
    Dawood S; Gonzalez-Angulo AM
    Cancer Biomark; 2012-2013; 12(6):241-50. PubMed ID: 23735944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant chemotherapy of breast cancer: tumor markers as predictors of pathologic response, recurrence, and survival.
    Precht LM; Lowe KA; Atwood M; Beatty JD
    Breast J; 2010; 16(4):362-8. PubMed ID: 20443786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.